Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Bone Diseases, Metabolic 3Prostatic Neoplasms 2Osteoporosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1Lung Neoplasms 1Leukemia 1Esophageal Neoplasms 1Dwarfism, Pituitary 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Gemcitabine 14Cisplatin 13Capecitabine 11Oxaliplatin 9Fluorouracil 9130-nm albumin-bound paclitaxel 9Paclitaxel 8pembrolizumab 7Ramucirumab 6Leucovorin 6Carboplatin 6Bevacizumab 6Albumin-Bound Paclitaxel 6Pemetrexed 4Nivolumab 4Irinotecan 4Everolimus 4Erlotinib Hydrochloride 4Docetaxel 4Cyclophosphamide 4trastuzumab deruxtecan 3Radiotherapy 3Afatinib 3zolbetuximab 2pralsetinib 2cabozantinib 2Trastuzumab 2Ipilimumab 2vosaroxin 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma × Risedronic Acid × Clear all
NCT01077817 2022-02-03

Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)

Organon and Co

Completed
684,815 enrolled 6 charts
Gastrointestinal

Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡